Skip to content
Peptide Atlas
All peptides

SS-31

Tier 2 · Preclinical
Also known as Elamipretide · MTP-131 · Bendavia

The strongest evidence is Tier 1: human randomized controlled trials (TAZPOWER Phase 3 in Barth syndrome, MMPOWER-3 Phase 3 in primary mitochondrial myopathy, PROGRESS-HF Phase 2 in HFrEF, EVOLVE Phase IIa, RENEW Phase 3 in dry AMD) plus FDA accelerated approval as Forzinity (September 19, 2025) for Barth syndrome. Important nuance: the two pivotal Phase 3 trials in mitochondrial myopathy and heart failure FAILED their primary endpoints, with benefit only in post-hoc subgroups. The Barth syndrome approval rested on just 12 patients and a split 10:6 advisory panel vote. Cognitive, anti-aging, renal, ophthalmic and metabolic effects remain largely animal/in-vitro. Many consumer dosing/PK details derive from low-tier vendor sources.

Half-life
~3.5 h
Routes
Subcutaneous injection · Intravenous infusion
Goals
longevity · cognitive · body composition · healing
Cost / mg
Not recorded

How it works

SS-31 (elamipretide) is a small synthetic peptide that homes in on the powerhouses of the cell — the mitochondria. It carries a positive charge and rapidly penetrates cells, accumulating hundreds to thousands of times over inside the inner mitochondrial membrane. There it binds tightly to cardiolipin, a special fat found only in mitochondria that is essential for keeping the energy-producing machinery organized and working. By protecting cardiolipin, SS-31 helps preserve mitochondrial structure, keeps the electron transport chain assembled, boosts ATP (energy) production, and reduces harmful reactive oxygen species at their source rather than mopping them up after the fact. It has been studied in Barth syndrome, mitochondrial myopathy, heart failure, kidney injury, and age-related macular degeneration, and in September 2025 received FDA accelerated approval (as Forzinity) to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

Overview

Overview

SS-31 — known clinically as elamipretide and also as MTP-131 and Bendavia — is a synthetic, mitochondria-targeted, cell-permeable aromatic-cationic tetrapeptide (sequence D-Arg-2',6'-dimethyltyrosine[Dmt]-Lys-Phe-NH2). It has a molecular formula of C32H49N9O5, a molecular weight of ~639.8-640.8 Da, and carries a net +3 charge at physiological pH (CAS# 736992-21-5).

It was discovered during opioid-receptor studies and developed in 2004 by Drs. Hazel Szeto and Peter Schiller (the "SS" reflects the Szeto-Schiller nomenclature), and has been studied since the early 21st century.

How it works

The peptide's alternating aromatic-cationic structure drives rapid cell penetration and accumulation at the inner mitochondrial membrane independent of membrane potential, with reported enrichment of more than 1,000-fold (up to 5,000-fold) above extracellular levels. Once there, SS-31 selectively binds cardiolipin — an anionic phospholipid found exclusively on the inner mitochondrial membrane (~20% of its lipid) that is essential for cristae formation, ETC supercomplex assembly, and ATP synthase function.

By binding cardiolipin at nanomolar affinity, SS-31:

  • preserves cristae curvature and stabilizes ETC supercomplexes (Complexes I, III, IV) and ATP synthase oligomers, improving coupling and raising ATP synthesis;
  • prevents cardiolipin peroxidation and cytochrome c peroxidase activity, limiting ROS production at the source;
  • prevents mitochondrial depolarization, inhibits mitochondrial permeability transition pore formation, and prevents Ca2+-induced swelling.

Note — contested mechanism: Sources disagree on whether SS-31 is best described as a mitochondria-targeted antioxidant that scavenges ROS, or as a structural agent that limits ROS production by stabilizing cardiolipin/ETC architecture. Both framings appear across the literature.

It is reported to have no effect on normal mitochondria.

Evidence and clinical development

SS-31/elamipretide has been evaluated across 7+ trials (including PROGRESS-HF, TAZPOWER, MMPOWER-3, ReCLAIM, EMBRACE, EVOLVE, and RENEW):

  • Barth syndrome (approved indication): The Phase 3 TAZPOWER trial (12 patients, 40 mg SC once daily, double-blind crossover) reported a mean +29.6 m improvement in 6-minute-walk distance over placebo during its 12-week placebo-controlled phase. The sustained 6MWT gains and improved LVEF/stroke volume reported at 168 weeks come from the open-label extension (TAZPOWER-OLE), which had no concurrent placebo comparator — so the long-term functional gains, unlike the +29.6 m figure, are not placebo-controlled. After a 2023 Complete Response Letter (citing small sample size) and a split 10:6 advisory-panel vote in October 2024, elamipretide received FDA accelerated approval on September 19, 2025 as Forzinity (NDA 215244) — the first disease-specific and first mitochondria-targeted drug approved — to improve muscle strength in adult and pediatric Barth syndrome patients weighing ≥30 kg.
  • Primary mitochondrial myopathy: The Phase 3 MMPOWER-3 trial (n=218, 40 mg/day SC, 24 weeks) did NOT meet its primary 6MWT endpoint (−3.2 m, p=0.69) nor fatigue score (p=0.37). Post-hoc, subjects with nuclear-DNA variants improved while mtDNA-variant subjects did not; the replisome cohort trended toward significance (p=0.06) and the CPEO subgroup improved significantly (p=0.0024).
  • Heart failure: In the Phase 2 PROGRESS-HF/EMBRACE trial (71 HFrEF patients, LVEF <40%), there was no significant change in LV end-systolic volume vs placebo, with strain signals in the high-dose cohort.
  • Dry AMD: The Phase 3 RENEW trial (~550 patients, ellipsoid-zone endpoint at 24 months) reached 50% enrollment by March 2025; development continues.
  • Renal: A single IV dose improved cortical perfusion after renal-artery stenting in the Phase IIa EVOLVE study.

Preclinical scope

Preclinical models show protective/restorative effects in heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, muscle atrophy/aging, atherosclerosis, osteoarthritis, diabetes, and glaucoma. Examples include restoration of state-3 respiration in aged mouse hearts within one hour, normalization of the ATP/ADP ratio (0.38→1.16) and Complex I/IV activity in a canine heart-failure model, 50-60% infarct-size reduction in rat/sheep ischemia-reperfusion, suppression of ferroptosis in diabetic cardiomyopathy and spinal-cord-injury models, and cognitive protection with enhanced BDNF signaling in LPS-treated and anesthesia-exposed mice.

Important: Cognitive, anti-aging, and most non-cardiac benefits remain animal/in-vitro only. Cognitive benefits have not been confirmed in humans, and there are zero clinical trials in cognitive impairment. The peptide is approved only for Barth syndrome — not for the other conditions studied.

Some consumer-facing sources market SS-31 directly and suggest pairing it with NAD+ precursors such as NMN for mitochondrial support; these are not established clinical recommendations.

What the research shows

249 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 19 human trial findings, 7 human study findings, 22 animal findings, 3 in vitro findings and 11 expert opinion findings.

  • human trialElamipretide was granted accelerated approval in the USA for use to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥ 30 kg1

  • human trialElamipretide is under phase III clinical development for use in the treatment of dry age-related macular degeneration1

  • human trialElamipretide is under phase III clinical development for use in the treatment of mitochondrial myopathies1

  • human trialClinical trials PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM have been conducted with Elamipretide2

  • human trialMMPOWER-3 clinical trial did not demonstrate a significant benefit of elamipretide treatment in a genotypically diverse population of adults with primary mitochondrial myopathy (PMM)3

  • human trialSubjects with disease-causing nuclear DNA (nDNA) pathogenic variants receiving elamipretide experienced an improvement in the six-minute walk test (6MWT)3

  • human trialCohort of subjects with mitochondrial DNA (mtDNA) pathogenic variants showed no difference versus placebo3

  • human trialThe mtDNA replisome post-hoc cohort displayed an improvement on the 6MWT, trending towards significant, in the elamipretide group when compared with placebo3

Show the remaining 54

  • human trial6MWT results at week 24 in subjects with replisome variants showed a significant change in the elamipretide group subjects who had chronic progressive external ophthalmoplegia (CPEO)3

  • human trialElamipretide had a beneficial effect in PMM patients with mtDNA replisome disorders3

  • human trialElamipretide at 40 mg/day subcutaneously did not significantly improve 6-minute walk test distance compared to placebo at 24 weeks in primary mitochondrial myopathy patients4

  • human trialElamipretide at 40 mg/day did not significantly improve total fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment compared to placebo at 24 weeks4

  • human trialElamipretide has shown promising improvements in cardiac hemodynamics at highest doses in early-phase clinical trials5

  • human trialElamipretide received FDA accelerated approval in September 2025 under the brand name Forzinity as the first disease-specific treatment for Barth syndrome7

  • human trialIn Barth syndrome Phase 3 TAZPOWER trial with 12 patients, 168-week data show sustained increase in 6-min-walk distance and improved LVEF with good tolerability26

  • human trialPrimary mitochondrial myopathy Phase 3 MMPOWER-3 trial with 218 patients: primary endpoint (6MWT) not met, but subgroup with nuclear-DNA mutations trended positive with acceptable safety26

  • human trialHeart failure HFrEF Phase 2 PROGRESS-HF trial with 71 patients showed no significant change in LV end-systolic volume vs. placebo; signals of improved strain in high-dose cohort26

  • human trialDry age-related macular degeneration Phase 3 RENEW trial with approximately 550 patients reached 50% enrollment by March 2025; endpoint is ellipsoid-zone attenuation at 24 months26

  • human trialSingle IV dose of SS-31 improved cortical perfusion after renal-artery stenting in Phase IIa EVOLVE study26

  • human studyClinical trials in heart failure and primary mitochondrial myopathy have failed14

  • human studySS-31 was studied in a phase 2/3 Barth syndrome trial with an open-label extension to 36+ weeks16

  • human study40 mg dose was used in phase 2/3 Barth syndrome trial and open-label extension lasting 12 weeks extended to 36+ weeks17

  • human studySafety data comes from Phase 1-3 clinical trials in heart failure patients, primary mitochondrial myopathy patients, and Barth syndrome patients17

  • human studySS-31 may enhance exercise capacity in older adults during clinical evaluation20

  • human studyTAZPOWER primary endpoint showed a mean improvement of 29.6 meters in six-minute walk test distance over placebo23

  • human studyTAZPOWER showed stroke volume improvement measured by cardiac MRI23

  • animalPreclinical studies have demonstrated protective and restorative efficacy of Elamipretide in models of heart failure, neurodegeneration, ischemia-reperfusion injury, metabolic syndromes, and muscle atrophy and weakness2

  • animalElamipretide has been shown to increase left ventricular ejection fraction in dog models of heart failure with reduced ejection fraction5

  • animalElamipretide has been shown to prevent left ventricular remodeling in rats5

  • animalIn the canine heart failure model, elamipretide restored Complex I and Complex IV enzymatic activity and normalized the ATP/ADP ratio from 0.38 to 1.167

  • animalIn a rat MI model, liposomal composite hydrogel containing SS-31 improves cardiac function by scavenging excess ROS, improving mitochondrial dysfunction, and promoting angiogenesis12

  • animalTreatment with elamipretide significantly ameliorated LPS-induced learning and memory impairment during behavioral tests13

  • animalIn aged mice exposed to anesthesia, SS-31 treatment protected cognitive function14

  • animalStudies exploring cardiac tissue show that SS-31 may support mitochondrial integrity during ischemia/reperfusion models20

  • animalSS-31 may improve left-ventricular function in certain test conditions20

  • animalResearch teams investigating neurodegeneration have reported that SS-31 may reduce markers of oxidative stress20

  • animalSS-31 may support synaptic health20

  • animalSS-31 may help maintain cognitive function in experimental Alzheimer's and Parkinson's models20

  • animalSS-31 may moderate neuroinflammation20

  • animalResearchers studying renal injury models have observed that SS-31 may help preserve mitochondrial structure in tubular cells20

  • animalSS-31 may support recovery after ischemic stress in kidney cells20

  • animalSS-31 may moderate oxidative damage in renal tissue20

  • animalSS-31 has been associated with better endurance capacity in studies involving aging and skeletal muscle20

  • animalSS-31 has been associated with higher ATP availability20

  • animalSS-31 has been associated with reduced fatigue markers during exertion20

  • animalA single SS-31 infusion in aged mouse hearts restored state 3 respiration and reduced hydrogen peroxide emission to levels seen in young controls within one hour23

  • animalIn ischemia-reperfusion models, SS-31 translated to 50 to 60% reductions in infarct size in rat and sheep hearts23

  • animalUnapproved peptides like SS-31 demonstrate favorable tissue repair and metabolic outcomes in animal models25

  • in vitroSS-31@Fer-1 significantly improved H/R-induced cardiomyocyte viability and reduced LDH and CK-MB levels10

  • in vitroSS-31 treatment markedly inhibited mitochondrial dysfunction and cell injury in cultured podocytes stimulated with high glucose11

  • in vitroSS-31 treatment partly reversed the damage mediated by ALCAT1 overexpression in podocytes11

  • expert opinionThese effects have not been confirmed in humans14

  • expert opinionNo human clinical trials demonstrate prevention of dementia, prevention of decline, or improved cognitive function14

  • expert opinionNo human research suggests benefits to patients with dementia14

  • expert opinionClinical trials have studied SS-31 in heart failure patients15

  • expert opinionSS-31 provides protection against ischaemia18

  • expert opinionSS-31 is in active clinical trials for various degenerative diseases18

  • expert opinionForzinity (elamipretide) was FDA-approved on September 19, 2025 under accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg22

  • expert opinionIn September 2025 it became the first mitochondria-targeted drug ever FDA-approved — as FORZINITY, for Barth syndrome24

  • expert opinionThe FDA granted accelerated approval to FORZINITY (elamipretide) for Barth syndrome on September 19, 202524

  • expert opinionElamipretide has been evaluated in 7+ clinical trials across multiple conditions24

  • expert opinionFDA advisory panel voted 10:6 for efficacy in Barth syndrome (October 2024)26

How it works

Based on 12 animal findings, 16 in vitro findings, 53 expert opinion findings and 15 theoretical findings.

  • animalSS-31 preserves cristae membranes during renal ischemia and prevents the mitochondrial swelling that typically accompanies ischemia-reperfusion injury7

  • animalSS-31 facilitates the assembly of CL-dependent protein complexes, including ETC supercomplexes (respirasomes) and ATP synthase oligomers, which increases the efficiency of electron transfer and reduces electron leak7

  • animalSS-31 acts as an inhibitor of mitochondrial oxidative damage12

  • animalSS-31 can target cytochrome c in the mitochondrial inner membrane of damaged cardiomyocytes12

  • animalSS-31 inhibits pathological ROS production, improving mitochondrial dysfunction12

  • animalMice treated with LPS exhibited mitochondrial dysfunction, oxidative stress, an inflammatory response, neural cell apoptosis, and loss of dendritic spines in the hippocampus13

  • animalElamipretide provided protective effects against mitochondrial dysfunction and oxidative stress13

  • animalElamipretide facilitated the regulation of brain-derived neurotrophic factor (BDNF) signaling, including the reversal of important synaptic-signaling proteins and increased synaptic structural complexity13

Show the remaining 88

  • animalSS-31 improves cognitive functions in models of cognitive impairment by promoting mitochondrial and synaptic health and decreasing inflammation and pyroptosis14

  • animalSS-31 inhibits the opening of the mitochondrial permeability transition pore that forms under mitochondrial stress14

  • animalSS-31 suppresses mitochondria-dependent ferroptosis in models of diabetic cardiomyopathy and spinal-cord injury26

  • animalSS-31 reduced neurite degeneration post-spinal-cord contusion in mice26

  • in vitroSS-31 decreases mitochondrial reactive oxygen species production6

  • in vitroSS-31 prevents mitochondrial depolarization6

  • in vitroSS-31 prevents mitochondrial permeability transition pore formation6

  • in vitroSS-31 prevents Ca2+-induced mitochondrial swelling6

  • in vitroSS peptides enable concentration more than 1,000-fold in the inner mitochondrial membrane (IMM) independently of membrane potential7

  • in vitroSS-31 works at the nanomolar level by selectively binding cardiolipin7

  • in vitroSS-31 partitions into the membrane interfacial region with an affinity directly proportional to surface charge, showing preferential interaction with CL-containing bilayers7

  • in vitroSS-31 stabilizes rather than disrupts lamellar membrane architecture, while causing saturable alterations in lipid packing that optimize the biophysical environment for protein-lipid interactions7

  • in vitroSS-31 modulates the surface electrostatics of mitochondrial membranes, reducing surface potential through its polybasic character and altering divalent cation (calcium) distribution within the interfacial region7

  • in vitroSS-31@Fer-1 reduced GSH and increased MDA levels, enhancing mitochondrial integrity and function compared to Fer-1 group10

  • in vitroSS-31@Fer-1 increased mitochondrial ROS and decreased MMP, indicating mitigation of H/R-induced cardiomyocyte cytotoxicity10

  • in vitroSS-31@Fer-1 maintained cellular iron homeostasis, as evidenced by increased expression of FTH, FTMT, FPN, and ABCB810

  • in vitroElevated levels of GPX4 and Nrf2 were observed in SS-31@Fer-1 group, while ACSL4 and PTGS2 levels were reduced10

  • in vitroSS-31@Fer-1 effectively suppressed ferroptosis in H/R-induced cardiomyocytes by maintaining cellular iron homeostasis, improving mitochondrial function, and inhibiting oxidative stress10

  • in vitroSS-31 is a cardiolipin antioxidant11

  • in vitroElamipretide (SS-31) is a novel mitochondrion-targeted antioxidant13

  • expert opinionElamipretide (Forzinity™) is a mitochondrial cardiolipin binder1

  • expert opinionElamipretide (SS-31) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin, a lipid found in the inner mitochondrial membrane2

  • expert opinionElamipretide stabilizes mitochondrial cristae structure, reduces oxidative stress, and enhances adenosine triphosphate (ATP) production2

  • expert opinionElamipretide has a unique structure allowing for uptake in a variety of cell types and highly selective mitochondrial targeting2

  • expert opinionSS-31 is a mitochondria-targeted drug that mitigates oxidative stress in dry AMD8

  • expert opinionSS-31 binds to cardiolipin in mitochondria to enhance ATP production and reduce oxidative stress15

  • expert opinionSS-31 is the only peptide with validated mechanism of action targeting and stabilizing cardiolipin in the inner mitochondrial membrane15

  • expert opinionSS-31 enhances ATP production by optimizing electron transport chain efficiency15

  • expert opinionSS-31 reduces oxidative stress at the inner mitochondrial membrane rather than just scavenging after the fact15

  • expert opinionSS-31 binds to cardiolipin in the inner mitochondrial membrane16

  • expert opinionSS-31 enhances ATP production by optimizing electron transport chain efficiency16

  • expert opinionSS-31 reduces oxidative stress at the inner mitochondrial membrane where ROS are produced16

  • expert opinionSS-31 (Elamipretide) is a mitochondrial peptide that repairs cellular bioenergetics and reduces oxidative stress at the source18

  • expert opinionSS-31 easily crosses cell membranes and binds specifically to cardiolipin in the inner mitochondrial membrane, stabilising energy production18

  • expert opinionSS-31 repairs the internal structure of mitochondria, allowing them to produce clean, efficient energy again18

  • expert opinionSS-31 restores mitochondrial function (ATP)18

  • expert opinionSS-31 reduces neuroinflammation18

  • expert opinionSS-31's relatively short half-life of approximately 2.5–3 hours appears critical to its selective cardiolipin binding and rapid tissue penetration19

  • expert opinionThe peptide's aromatic-cationic structure drives selective accumulation at the inner mitochondrial membrane where cardiolipin resides19

  • expert opiniontissue-level activity persists through the membrane-binding phase rather than requiring continuous plasma replenishment19

  • expert opinionSS-31 is a small synthetic tetrapeptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH₂) designed to selectively associate with cardiolipin, a unique lipid found in the inner mitochondrial membrane20

  • expert opinionSS-31 is reported to concentrate inside mitochondria themselves — where oxidative stress originates20

  • expert opinionResearchers report that SS-31 may enter cells and localize to mitochondria20

  • expert opinionSS-31 may bind to cardiolipin to stabilize mitochondrial membranes20

  • expert opinionSS-31 may support electron transport chain efficiency20

  • expert opinionSS-31 may reduce formation of reactive oxygen species (ROS)20

  • expert opinionSS-31 may help prevent cytochrome-c release, which is tied to cell death20

  • expert opinionSS-31 may maintain mitochondrial shape and structure during stress20

  • expert opinionSS-31 is a small synthetic peptide designed to concentrate in mitochondria, the cellular structures that generate much of the body's ATP through oxidative phosphorylation21

  • expert opinionSS-31 has proposed interaction with mitochondrial cardiolipin, a specialized lipid in the inner mitochondrial membrane involved in electron transport chain organization and mitochondrial bioenergetics21

  • expert opinionSS-31 is proposed to localize near the inner mitochondrial membrane and support mitochondrial structure and bioenergetics through cardiolipin-associated effects21

  • expert opinionSS-31 is a synthetic four-amino-acid peptide22

  • expert opinionSS-31 moves into the inner mitochondrial membrane and binds a phospholipid called cardiolipin22

  • expert opinionBy binding cardiolipin, SS-31 helps stabilize that scaffold under stress22

  • expert opinionSS-31 is a water-soluble, cell-permeable peptide designed to reach the inner mitochondrial membrane within minutes of administration23

  • expert opinionPrimary target is cardiolipin on the inner mitochondrial membrane23

  • expert opinionCardiolipin anchors cytochrome c and stabilizes electron transport chain complexes I, III, and IV23

  • expert opinionSS-31 binds selectively to cardiolipin through electrostatic and hydrophobic interactions23

  • expert opinionSS-31 prevents cytochrome c peroxidase activity and preserves normal electron flow, reducing superoxide generation23

  • expert opinionSS-31 does not function as a conventional antioxidant that scavenges free radicals after they form, but limits ROS production at the source23

  • expert opinionSS-31 (Elamipretide, MTP-131) is a synthetic tetrapeptide that binds directly to cardiolipin — a phospholipid found only in the mitochondrial inner membrane24

  • expert opinionSS-31 stabilizes the electron transport chain and protects mitochondrial architecture24

  • expert opinionCardiolipin constitutes ~20% of the inner membrane's lipid composition24

  • expert opinionSS-31's alternating aromatic and basic residues (D-Arg-dimethylTyr-Lys-Phe-NH₂) give it high affinity for cardiolipin's negatively charged head groups24

  • expert opinionSS-31 stabilizes the cristae architecture and electron transport chain supercomplexes (Complexes I, III, IV)24

  • expert opinionSS-31 prevents cardiolipin peroxidation, keeping cytochrome c in its functional role24

  • expert opinionBy stabilizing Complex I and III, SS-31 reduces electron leak and decreases mitochondrial ROS production24

  • expert opinionSS-31 restores cristae architecture even in aged or diseased mitochondria24

  • expert opinionIts alternating charge pattern facilitates rapid cell penetration independent of membrane potential24

  • expert opinionSS-31 is a cell-permeable, aromatic–cationic tetrapeptide designed to concentrate in the mitochondrial matrix26

  • expert opinionSS-31 forms electrostatic and hydrophobic interactions with cardiolipin, preserving cristae curvature and electron-transport-chain super-complex organisation26

  • expert opinionImproved ETC coupling raises ATP synthesis and reduces mitochondrial ROS leak26

  • expert opinionSS-31/Elamipretide has known mechanisms of cytoprotection in AMD28

  • theoreticalElamipretide maintains cellular biogenetics and prevents reactive oxygen species-induced cell damage by targeting and stabilizing the cardiolipin-cytochrome c supercomplex5

  • theoreticalSS-31 is a mitochondria-targeting antioxidant6

  • theoreticalThe kidneys, specifically proximal tubules, have a high mitochondria density due to ATP requirements for solute reabsorption and fluid and electrolyte balance regulation6

  • theoreticalROS play a key role in various renal diseases including ischemia-reperfusion injury, drug-induced acute kidney injury, chronic kidney disease, diabetic nephropathy, and hypertensive kidney damage6

  • theoreticalSS-31 is a synthetic mitochondria-targeted tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine(Dmt)-Lys-Phe-NH27

  • theoreticalCardiolipin is an anionic phospholipid uniquely expressed on the IMM that is essential for cristae formation, electron transport chain (ETC) supercomplex assembly, and ATP synthase function7

  • theoreticalSS-31 is an antioxidant that targets mitochondrial dysfunction as an emerging therapeutic strategy9

  • theoreticalSS-31 is a small peptide (D-Arg dimethyl-Tyr-Lys-Phe-NH2) that accumulates in mitochondria and scavenges reactive oxygen species14

  • theoreticalSS-31 binds to cardiolipin, a lipid exclusively expressed on the inner mitochondrial membrane14

  • theoreticalSS-31 binds to cardiolipin in mitochondria to increase ATP production17

  • theoreticalSS-31 reduces oxidative stress17

  • theoreticalSS-31 is a mitochondria-targeted tetrapeptide with molecular formula D-Arg-Dmt-Lys-Phe-NH₂23

  • theoreticalSS-31 carries a net charge of +3 at physiological pH, driving its accumulation across the mitochondrial membrane potential in a concentration-dependent manner23

  • theoreticalSS-31 is a mitochondria-targeted tetrapeptide that optimizes mitochondrial function and reduces oxidative damage30

  • theoreticalSS-31 concentrates in inner mitochondrial membrane, optimizes electron transport and reduces ROS production30

Dosing

Based on 2 human trial findings, 4 human study findings, 12 expert opinion findings and 3 anecdotal findings.

  • human trialThe TAZPOWER trial used daily subcutaneous dosing22

  • human trial40 mg subcutaneously once daily was the studied arm in TAZPOWER and is now the Forzinity recommended dose for patients ≥30 kg22

  • human studyStandard dose is 40 mg once daily for 12 weeks16

  • human studyTAZPOWER trial enrolled 12 patients with genetically confirmed Barth syndrome receiving elamipretide 40 mg subcutaneously once daily for 12 weeks in a double-blind, crossover design23

  • human studyEscalated dose of 60 mg daily sub-q is being evaluated in open-label primary mitochondrial myopathy cohorts26

  • human studyAcute IV studies use 0.05 mg kg⁻¹ h⁻¹ infusion over 1–3 hours for renal-stent or STEMI pilot trials26

  • expert opinionStandard dose is 40 mg subcutaneous once daily for 12 weeks (extended in open-label to 36+ weeks) in the phase 2/3 Barth syndrome trial15

  • expert opinionSS-31 can be taken regardless of food timing15

Show the remaining 13

  • expert opinionMost published protocols dose SS-31 once or twice daily despite the short plasma half-life because tissue-level activity persists through membrane interaction rather than bloodstream presence19

  • expert opinionDifferent studies have explored 5–10 mg/day equivalent for general mitochondrial support models20

  • expert opinionDifferent studies have explored 20–40 mg/day equivalent in more intensive investigations (cardiac, renal, fatigue models)20

  • expert opinionSubcutaneous administration in most experiments20

  • expert opinion4–12 week timeframes depending on the protocol20

  • expert opinionForzinity comes as a 280 mg / 3.5 mL (80 mg/mL) ready-to-use solution22

  • expert opinionDosing frequency is once daily, same time each day per Forzinity label22

  • expert opinionFor adults with severe renal impairment (eGFR <30 mL/min, not on dialysis), the FDA label recommends 20 mg subcutaneously once daily22

  • expert opinionSS-31 is administered subcutaneously or intravenously in clinical trials24

  • expert opinionSS-31 chronic ambulatory dose is 40 mg subcutaneous injection once daily26

  • anecdotalStandard dose is 40 mg once daily via subcutaneous injection17

  • anecdotalDose range is 5-40 mg17

  • anecdotalCycle length is 4-6 weeks17

How the body handles it

Based on 1 human trial finding, 2 human study findings, 3 animal findings, 9 expert opinion findings, 3 anecdotal findings and 3 theoretical findings.

  • human trialPharmacokinetic (exposure-response) analyses in the nDNA cohort showed a weak positive correlation between plasma elamipretide concentration and 6MWT improvement3

  • human studyHalf-life is approximately 4 hours subcutaneous7

  • human studyHalf-life is approximately 3 to 4 hours in healthy volunteers23

  • animalSS-31 is rapidly absorbed after subcutaneous administration and concentrates in the kidney, but is also taken up by the heart, liver, skeletal muscle, and lungs14

  • animalBrain concentrations are low compared to plasma, but it does cross the blood-brain barrier14

  • animalA 2015 study in Circulation Research (Dai et al.) measured SS-31 concentration in cardiac tissue following IV bolus in rats, finding detectable peptide in myocardial mitochondria 6–8 hours after plasma levels dropped below the limit of quantification19

  • expert opinionHalf-life is 3-4 hours15

  • expert opinionBioavailability is ~92% via subcutaneous route15

Show the remaining 13

  • expert opinionSS-31 half life in human plasma is approximately 2.5–3 hours following intravenous administration19

  • expert opiniontissue residence times in cardiac and skeletal muscle extend significantly longer due to mitochondrial membrane binding19

  • expert opinionpeak plasma concentration (Cmax) occurring within 15–30 minutes IV and 30–60 minutes subcutaneously19

  • expert opinioncirculating peptide is cleared via renal filtration and metabolism, primarily through peptidase degradation of the C-terminal dimethyltyrosine residue19

  • expert opinionmitochondrial tissue residence extends 8–12 hours due to cardiolipin binding kinetics that persist after systemic clearance19

  • expert opinionWithin minutes of subcutaneous injection, SS-31 reaches mitochondria at concentrations roughly 1,000- to 5,000-fold above extracellular levels23

  • expert opinionSS-31 reaches millimolar concentrations inside mitochondria within minutes of systemic administration26

  • anecdotalSubcutaneous injection has high bioavailability with most dose reaching bloodstream17

  • anecdotalSS-31 reaches peak blood levels within 30-60 minutes17

  • anecdotalSubcutaneous injection has approximately 92% bioavailability17

  • theoreticalSS-31 has a molecular weight of 640.8 Da7

  • theoreticalHalf-life is 3-4 hours16

  • theoreticalBioavailability via subcutaneous route is ~92%16

Safety and side effects

Based on 4 human trial findings, 5 human study findings, 1 in vitro finding, 8 expert opinion findings and 1 anecdotal finding.

  • human trialElamipretide treatment was well-tolerated with most adverse events being mild to moderate in severity4

  • human trialSubcutaneous elamipretide is well-tolerated in patients with primary mitochondrial myopathy4

  • human trialIn early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events5

  • human trialInjection-site erythema and pruritus are the most common adverse events, usually grade 1–2 and self-limiting26

  • human studySS-31 treatment leads to a few adverse events, though mostly mild14

  • human studyThe most common adverse event with SS-31 is injection site reaction14

  • human studySS-31 has demonstrated a favorable safety profile across multiple clinical trials including studies lasting up to 24 weeks17

  • human studyMost common adverse event is mild injection site reactions17

Show the remaining 11

  • human studyNo mitochondria-specific safety signal such as lactic acidosis has been observed across more than 2,000 patient-years26

  • in vitroSS-31 has no effects on normal mitochondria6

  • expert opinionTreatments longer than 4 weeks have not been studied, so long-term safety of SS-31 is not established in humans14

  • expert opinionElamipretide received FDA approval for Barth syndrome in September 202517

  • expert opinionIrritation at the injection site is a common adverse effect18

  • expert opinionSafety and effectiveness of Forzinity not established for patients <30 kg22

  • expert opinionFDA issued a Complete Response Letter in February 2023 citing small sample size and requesting additional evidence of clinical benefit23

  • expert opinionRigorous human safety data for unapproved peptides like SS-31 are scarce25

  • expert opinionThere is potential for serious harm to patients from unapproved peptides including SS-3125

  • expert opinionChallenges in retinal therapies include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence27

  • anecdotalSide effects include injection site reactions, headache, and fatigue17

What people use it for

Based on 2 human trial findings, 2 human study findings, 2 animal findings, 10 expert opinion findings and 1 theoretical finding.

  • human trialElamipretide became the first disease-specific treatment approved for Barth syndrome1

  • human trialSS-31 has been investigated in clinical trials for heart failure with reduced ejection fraction (HFrEF), primary mitochondrial myopathy, dry age-related macular degeneration (AMD), and renal ischemia-reperfusion injury7

  • human studySS-31 is administered via subcutaneous injection16

  • human studyEMBRACE randomized 71 patients with heart failure and left ventricular ejection fraction <40% who had recently experienced a heart failure hospitalization23

  • animalPreclinical studies suggest benefits in muscle aging, atherosclerosis, ischemia, osteoarthritis, diabetes, and glaucoma14

  • animalSS-31 shows photoreceptor preservation in intermediate AMD models26

  • expert opinionSS-31 can be taken regardless of food timing16

  • expert opinionSS-31 pairs well with NAD+ precursors like NMN for mitochondrial support16

Show the remaining 9

  • expert opinionSS-31 has been studied in heart failure and myopathies18

  • expert opinionSS-31 peptide, also known as elamipretide in clinical development and regulatory contexts, is a small mitochondria-targeted tetrapeptide studied for conditions involving mitochondrial dysfunction, cardiolipin biology, oxidative stress, and impaired cellular energy production21

  • expert opinionSS-31 has been studied for effects on mitochondrial oxidative stress and reactive oxygen species21

  • expert opinionmitochondrial dysfunction is studied in inherited mitochondrial disease, skeletal muscle fatigue, cardiac disease, kidney injury, ageing, and other conditions21

  • expert opinionSS-31 (elamipretide) is a prominent peptide marketed direct to patients25

  • expert opinionIntravitreal injections remain the standard for treating common retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy27

  • expert opinionElamipretide is mentioned as an emerging therapy for retinal disease that has achieved FDA approval within the past five years or advanced to Phase 3 development27

  • expert opinionSS-31/Elamipretide is a potential candidate for AMD therapy28

  • theoreticalElamipretide may have therapeutic potential in preventing damage from oxidative stress and neuroinflammation that contribute to perioperative neurocognitive disorders (PND)13

Other findings

Based on 10 expert opinion findings, 2 anecdotal findings and 1 theoretical finding.

  • expert opinionSS-31 was discovered while carrying out studies on opioid receptors6

  • expert opinionSS-31 has been extensively studied since the early twenty-first century6

  • expert opinionSS-31 was developed in 2004 by Dr. Hazel Szeto and Dr. Peter Schiller at Weill Cornell Medical College / University of Montreal15

  • expert opinionPublications describe reconstitution with sterile diluent, refrigeration after mixing, stability for several weeks at cold temperatures, and avoiding freeze–thaw cycles20

  • expert opinionthe same compound is often called elamipretide; earlier development names include MTP-131 and Bendavia21

  • expert opinionElamipretide is classified as a tetrapeptide because it contains four amino acid residues21

  • expert opinionFDA Priority Review PDUFA action date for Barth syndrome NDA is April 29, 202526

  • expert opinionSS-31 chemical composition is D-Arg-Dmt-Lys-Phe-NH₂26

Show the remaining 5

  • expert opinionFrequent intravitreal administration creates significant treatment burden due to limited drug half-life and the chronic nature of these conditions27

  • expert opinionPromising innovations include sustained-release intravitreal implants, topical and subcutaneous delivery systems, and targeted methods like suprachoroidal and subretinal injections27

  • anecdotalReconstituted SS-31 should be used within 28 days when stored at 36-46°F (2-8°C)17

  • anecdotalLyophilized powder remains stable for up to 2 years when frozen at -20°C or below17

  • theoreticalSS-31 (also known as MTP-131, elamipretide, and Bendavia) is D-Arg-Dmt-Lys-Phe-NH26

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Contested

Whether SS-31 acts as a direct antioxidant/ROS scavenger or works structurally is described differently across sources

Several sources (SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ..., SS-31 (also known as Elamipretide®, Bendavia®, and ..., SS-31 Protocol - Dosing, Benefits & Warnings | Peptilogical, Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice., ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease.) characterize SS-31 as a mitochondria-targeted antioxidant that scavenges reactive oxygen species. Other sources (SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com, SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative) explicitly state SS-31 does NOT function as a conventional antioxidant scavenging free radicals after they form, but instead limits ROS production at the source by stabilizing cardiolipin/ETC structure.

Limited evidence

The two pivotal Phase 3 trials failed their primary endpoints, with benefit only in post-hoc subgroups

MMPOWER-3 (n=218) did not meet its primary 6MWT endpoint (p=0.69); only post-hoc subgroups with nuclear-DNA/replisome/CPEO variants showed benefit, with the replisome cohort only trending toward significance (p=0.06). PROGRESS-HF (n=71) showed no significant change in LV end-systolic volume. One review states heart failure and mitochondrial myopathy trials 'have failed.' Barth syndrome approval rested on just 12 patients (TAZPOWER) and a split 10:6 advisory vote, following a 2023 Complete Response Letter for small sample size.

Contested

Approval status is stated inconsistently across sources

SS-31 (Elamipretide) Peptide Therapy — Mechanism, Evidence & Clinical Pearls for Medical Professionals - Dr. Raj Singh lists a PDUFA date of April 29, 2025 and describes the drug as pre-approval, while SS-31 (Elamipretide): Research Evidence & Safety Profile | PeptideInsight, SS-31 Elamipretide: Phase 2/3 Clinical Trial Data & Mechanism, SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026), SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, and Elamipretide: First Approval. report FDA accelerated approval as Forzinity on September 19, 2025. This reflects different source dates rather than genuine disagreement, but readers should note the peptide was only approved for Barth syndrome, not the other conditions.

Contested

Reported plasma half-life values differ (2.5-3 h vs 3-4 h)

SS-31 Half Life — What Researchers Must Know reports a human plasma half-life of approximately 2.5-3 hours (IV), while SS-31 (Elamipretide): Research Evidence & Safety Profile | PeptideInsight, SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com, SS-31 (also known as Elamipretide®, Bendavia®, and ..., SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative, SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, and SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative report approximately 3-4 hours (subcutaneous or in dogs). The differences may reflect route of administration and species.

Limited evidence

Cognitive, anti-aging, and most non-cardiac benefits are animal/in-vitro only, not confirmed in humans

SS-31 (also known as Elamipretide®, Bendavia®, and ... states cognitive benefits have not been confirmed in humans and there are zero clinical trials for cognitive impairment; SS-31 Peptide (Elamipretide): The Ultimate Guide to Mitochondrial Health, Benefits, and Dosing — Peptide Resource describes many benefits with 'may' language from animal/experimental models. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. notes rigorous human safety data for the peptide as an unapproved product are scarce.

Other

Many dosing and pharmacokinetic claims come from low-tier commercial peptide-vendor sources

Detailed consumer dosing protocols (5-40 mg ranges, 4-6 week cycles, ~92% bioavailability, storage, NMN pairing) derive largely from tier 3-4 vendor/protocol sites (SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026), SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative, SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative, SS-31 Peptide (Elamipretide): The Ultimate Guide to Mitochondrial Health, Benefits, and Dosing — Peptide Resource, SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative) rather than peer-reviewed trials; some are explicitly anecdotal or theoretical.

Single source

Extended mitochondrial tissue residence (8-12 h) rests on a single source citing one 2015 rat study

The claim that mitochondrial tissue residence extends 8-12 hours despite short plasma half-life, and that peptide remained detectable in rat myocardial mitochondria 6-8 hours after plasma clearance, comes only from SS-31 Half Life — What Researchers Must Know (a vendor site referencing Dai et al. 2015).

Inconsistency

Safety section states 'treatments longer than 4 weeks have not been studied' while the profile elsewhere describes 24-we…

These are directly contradictory. Either the 4-week claim (from a single review, SS-31 (also known as Elamipretide®, Bendavia®, and .../Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.) is being misapplied to elamipretide generally, or the trial durations reported elsewhere are wrong. A reader cannot reconcile 'no data beyond 4 weeks' with a 168-week trial and 2,000 patient-years of safety exposure in the same document.

Inconsistency

EMBRACE and PROGRESS-HF are conflated as a single 71-patient HFrEF trial

EMBRACE (EMBRACE STEMI) was a reperfusion/infarct trial in first-time anterior STEMI patients, not a 71-patient HFrEF study. PROGRESS-HF was the ~71-patient HFrEF trial in patients with recent HF hospitalization and LVEF<40%. Merging them ('PROGRESS-HF/EMBRACE trial (71 HFrEF patients)') misattributes trial population and design.

What you may have heard

'Reported to have no effect on normal mitochondria' stated as established fact in both mechanism sections

This absolute claim rests on a single tier-2 source (SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ..., a kidney-injury paper). An absence-of-effect claim on 'normal' mitochondria is difficult to prove and should be hedged; presenting it unqualified in the plain and technical mechanism overstates the evidence.

What you may have heard

'Reaches millimolar/high concentrations inside mitochondria within minutes' — millimolar is a very high specific claim

Millimolar intramitochondrial concentration is an extraordinary figure that would exceed most cardiolipin-binding stoichiometry expectations; it is sourced only to tier-3 expert-opinion sites (SS-31 (Elamipretide) Peptide Therapy — Mechanism, Evidence & Clinical Pearls for Medical Professionals - Dr. Raj Singh, SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com) and sits uneasily beside the more conservative '>1,000-fold enrichment' framing used elsewhere. Worth verifying against primary PK data.

Other

Once-daily dosing justified largely by 8-12 h mitochondrial residence, which the profile itself flags as a single vendor…

The rationale bridging a ~3.5 h plasma half-life to once-daily dosing leans on the extended tissue-residence claim, which is explicitly single-source and animal-only (SS-31 Half Life — What Researchers Must Know/Dai 2015). The approved once-daily regimen is regulatory fact, but the mechanistic justification should not be presented as if well-established.

What you may have heard

'first disease-specific and first mitochondria-targeted drug approved' phrasing

'First disease-specific drug approved' is vague/likely inaccurate as stated (many disease-specific drugs exist). The defensible claim is 'first drug approved for Barth syndrome' and 'first mitochondria-targeted therapeutic.' The current wording risks confusing readers.

Limited evidence

The muscle and walking benefits reported for elamipretide in Barth syndrome come from a single 12-patient trial and remain far from firmly established.

The frequently quoted 29.6-metre gain in six-minute-walk distance comes from TAZPOWER, which enrolled only 12 genetically confirmed Barth syndrome patients. The evidence was thin enough that the FDA first issued a Complete Response Letter in 2023 citing the small sample size, and an advisory committee split 10 votes to 6 on efficacy. When accelerated approval was finally granted in September 2025, it rested on an intermediate measure — improvement in knee-extensor muscle strength — rather than on the walking distance or long-term functional gains, and continued approval may depend on a confirmatory trial. The sustained improvements reported out to 168 weeks come from an open-label extension that had no placebo group for comparison.

Using it with other compounds

Check a stack
  • MOTS-cComplementary

    No documented conflict

    Both aim to protect and improve mitochondria but by different routes: MOTS-c works upstream through AMPK activation and Nrf2/ARE antioxidant gene expression, while SS-31 physically stabilizes cardiolipin and the electron-transport-chain supercomplexes to reduce ROS at the source. These are non-overlapping mechanisms converging on the same goal of better mitochondrial function and lower oxidative stress, making them a plausibly synergistic pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanisms clearly establish both shared dimensions. (1) Mitochondrial_function: MOTS-c improves mitochondrial function via AMPK activation and metabolic pathway modulation (folate-methionine cycle disruption); SS-31 directly stabilizes cardiolipin, ETC supercomplexes, and ATP synthase to enhance oxidative phosphorylation and ATP synthesis. Both target mitochondrial function but through distinct routes. (2) Anti_inflammatory: MOTS-c has anti-inflammatory effects via STAT3/IL-10 regulation and Keap1-Nrf2 pathways; SS-31 modulates inflammation/pyroptosis through ferroptosis suppression and BDNF signaling. The explanation correctly identifies these as non-overlapping upstream (MOTS-c: gene expression/AMPK) versus downstream (SS-31: direct structural/bioenergetic) mechanisms converging on mitochondrial protection and ROS reduction. This is a valid complementary relationship supported by the provided mechanisms.

    Shares mitochondrial function · anti inflammatory

  • GHK-CuComplementary

    No documented conflict

    GHK-Cu supports cytosolic antioxidant capacity (SOD1, Nrf2) while SS-31 specifically stabilizes cardiolipin and cuts mitochondrial ROS at the source. Different compartments, complementary antioxidant coverage.

    Tier 4Theoretical — not established
  • SemaxComplementary

    No documented conflict

    SS-31 protects neurons by stabilizing mitochondria and reducing ROS, while Semax protects them through neurotrophin (BDNF/TrkB) signaling. The mitochondrial-protection plus neurotrophic-signaling combination targets different arms of neuroprotection, making them potentially complementary.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly support the claimed shared dimensions. Semax directly targets BDNF/NGF-TrkB neurotrophin signaling and produces anti-inflammatory effects through NF-kB modulation and interferon signaling. SS-31 explicitly lists BDNF synaptic signaling and inflammation/pyroptosis modulation in its pathways, plus anti-inflammatory in approved tags. The explanation correctly identifies that they operate through distinct mechanistic routes (Semax via neurotrophin signaling and dopaminergic/serotonergic modulation; SS-31 via mitochondrial stabilization and ROS reduction) that converge on shared outcomes (neuroprotection, anti-inflammation, BDNF signaling). This represents genuine complementarity—different upstream mechanisms producing overlapping protective effects—which is well-justified by the provided mechanism material.

    Shares anti inflammatory · BDNF signaling

  • EpithalonComplementary

    No documented conflict

    SS-31 stabilizes cardiolipin and cuts mitochondrial ROS at the source, whereas Epithalon's reported benefits run through telomerase and general antioxidant/senescence pathways. Both reduce oxidative/mitochondrial aging burden via unrelated mechanisms, making them plausibly complementary.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms establish mitochondrial_function as a shared dimension through distinct pathways: SS-31 directly targets cardiolipin, mPTP, and ETC supercomplexes to reduce mitochondrial ROS production and preserve mitochondrial structure; Epithalon activates telomerase and antioxidant pathways while modulating mitochondrial ROS. The proposed relationship as 'complementary' is justified—they address mitochondrial aging burden through unrelated mechanisms (direct mitochondrial targeting vs. telomerase/antioxidant upregulation), making them mechanistically non-overlapping yet synergistic for the shared dimension of mitochondrial function. Both peptides' approved tags include 'mitochondrial_function,' confirming this shared dimension is recognized in their mechanism profiles.

    Shares mitochondrial function

  • HexarelinComplementary

    Worth caution

    Both have cardioprotective, anti-apoptotic profiles against ischemia-reperfusion injury but by entirely different mechanisms: hexarelin via CD36/GH-independent inotropy and inflammasome suppression, SS-31 by stabilizing mitochondrial cardiolipin and reducing mitochondrial ROS. Convergence on cardiac protection makes them mechanistically complementary in research settings.

    Tier 4Theoretical — not established
  • HumaninComplementary

    May be complementary

    Both aim to protect mitochondria and reduce oxidative/ischemic injury, but by different means: SS-31 physically stabilizes the inner-membrane cardiolipin and electron-transport supercomplexes to preserve ATP output and cut ROS, whereas humanin signals through receptors to trigger anti-apoptotic and anti-inflammatory programs. One protects mitochondrial machinery directly, the other signals survival — a genuinely complementary combination.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the complementary relationship with the claimed shared dimensions. The mechanism material explicitly establishes: (1) Both target mitochondrial_function—SS-31 directly stabilizes cardiolipin, cristae, and ETC supercomplexes to preserve ATP and reduce ROS; humanin enhances mitochondrial biogenesis and bioenergetics. (2) Both target anti_inflammatory—SS-31 modulates inflammation/pyroptosis; humanin reduces pro-inflammatory cytokines via JAK2/STAT3 and SIRT1. (3) The explanation accurately characterizes their distinct mechanisms: SS-31 acts through direct physical stabilization of inner-membrane structures and oxidative phosphorylation, while humanin acts through receptor signaling (FPR2/FPR3, gp130) to trigger cytoprotection and anti-apoptotic programs. These are genuinely different mechanistic approaches (direct structural vs. signaling-mediated) that converge on shared protective outcomes, meeting the definition of complementarity. The mechanisms do not contradict this relationship; they substantiate it.

    Shares mitochondrial function · anti inflammatory

  • CerebrolysinComplementary

    May be complementary

    SS-31 protects mitochondrial energy production and reduces oxidative stress at the cardiolipin level, while Cerebrolysin improves neuronal energy metabolism and provides neurotrophic support. Pairing a targeted mitochondrial protector with a neurotrophic mixture addresses neuroprotection from two angles. Combination evidence is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the three claimed shared dimensions: (1) mitochondrial_function—SS-31 directly targets cardiolipin and ETC supercomplexes to improve ATP synthesis and mitochondrial structure; Cerebrolysin improves neuronal energy metabolism and is tagged with mitochondrial_function. (2) anti_inflammatory—SS-31 modulates inflammation/pyroptosis; Cerebrolysin explicitly includes anti-inflammatory modulation of microglia and TNF-α downregulation. (3) BDNF_signaling—both are explicitly tagged with BDNF_signaling, and SS-31's mechanisms include BDNF synaptic signaling while Cerebrolysin upregulates BDNF. The proposed 'complementary' relationship is justified: SS-31 provides targeted mitochondrial protection at the cardiolipin/ETC level, while Cerebrolysin provides broader neurotrophic and neuroprotective effects including energy metabolism support. These mechanisms operate on overlapping but distinct targets and pathways, supporting a complementary rather than redundant pairing. The explanation accurately reflects both mechanisms.

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • NoopeptComplementary

    No documented conflict

    SS-31 protects neurons by stabilizing mitochondria and cutting oxidative stress, while Noopept provides neurotrophic (BDNF) and anti-excitotoxic support. Both share mitochondrial, anti-inflammatory and BDNF-related tags but act through different targets, so they can converge on neuroprotection from complementary angles.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly support the three claimed shared dimensions. Noopept lists approved tags: mitochondrial_function, anti_inflammatory, BDNF_signaling. SS-31 lists identical approved tags: mitochondrial_function, anti_inflammatory, BDNF_signaling. The mechanisms confirm distinct targets and pathways: SS-31 acts directly on cardiolipin, mPTP, and ETC complexes to stabilize mitochondria and reduce ROS; Noopept acts via AMPA/TrkB receptors, HIF-1 stabilization, and cholinergic signaling to provide neuroprotection and BDNF signaling. Both demonstrate anti-inflammatory effects through different mechanisms (SS-31 via ferroptosis/pyroptosis suppression; Noopept via stress kinase repression and antioxidant action). The explanation accurately characterizes them as converging on neuroprotection through complementary but distinct mechanistic pathways, which is justified by the provided material.

    Shares mitochondrial function · anti inflammatory · BDNF signaling

  • CortexinComplementary

    May be complementary

    SS-31 protects neurons at the mitochondrial level (cardiolipin/ETC stabilization, reduced mitochondrial ROS), while Cortexin provides receptor-level anti-excitotoxic, antioxidant and anti-apoptotic protection. Two different arms of neuroprotection (energy metabolism vs. glutamate/apoptosis) that plausibly complement one another.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly support the claimed shared dimensions: (1) anti_inflammatory is documented for both (Cortexin: 'Anti-inflammatory (central and systemic)' and 'Neuroinflammatory pathways'; SS-31: 'Inflammation/pyroptosis modulation' and approved tag 'anti_inflammatory'), and (2) BDNF_signaling is documented for both (Cortexin: 'BDNF-like / NGF-like neurotrophic signaling' and approved tag 'BDNF_signaling'; SS-31: 'BDNF synaptic signaling' and approved tag 'BDNF_signaling'). The explanation correctly identifies distinct mechanistic pathways: Cortexin operates via glutamatergic/GABAergic receptor modulation, caspase inhibition, and antioxidant effects, while SS-31 operates via mitochondrial cardiolipin stabilization, ETC coupling, and mitochondrial ROS reduction. These represent complementary neuroprotective mechanisms at different cellular levels (receptor/cytoplasmic vs. mitochondrial), justifying the 'complementary' relationship type.

    Shares anti inflammatory · BDNF signaling

  • KlothoComplementary

    May be complementary

    Both reduce oxidative stress and inflammation but at different points: SS-31 stabilizes the inner mitochondrial membrane (cardiolipin) to cut ROS production at the source, while Klotho boosts downstream Nrf2/FoxO antioxidant defenses and suppresses NLRP3/NF-κB inflammation. Together they address oxidative damage both where it is generated and how the cell defends against it.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support anti-inflammatory activity through distinct but complementary pathways. SS-31 reduces mitochondrial ROS production (the source of oxidative stress) via cardiolipin stabilization and electron transport chain optimization, while Klotho activates downstream antioxidant defenses (Nrf2, FoxO pathways) and directly suppresses inflammatory signaling (NLRP3 inflammasome, NF-κB). The proposed relationship accurately reflects that they target oxidative stress and inflammation at different mechanistic levels—upstream (mitochondrial ROS generation) versus downstream (cellular antioxidant response and inflammatory mediators). Both mechanisms explicitly support the anti_inflammatory tag, and the explanation correctly maps their distinct contributions to a complementary relationship.

    Shares anti inflammatory

Safety and side effects

Safety and Tolerability

Across clinical trials, elamipretide/SS-31 has generally been well-tolerated, with most adverse events mild to moderate.

Most common adverse events

  • Injection-site reactions (erythema, pruritus, irritation) — usually grade 1-2 and self-limiting
  • Headache
  • Fatigue

Notable safety observations

  • No severe adverse events reported in early-phase trials.
  • No mitochondria-specific safety signal (such as lactic acidosis) observed across more than 2,000 patient-years.

Limitations and cautions

  • Safety and effectiveness of Forzinity are not established for Barth syndrome patients weighing less than 30 kg.
  • For adults with severe renal impairment (eGFR <30 mL/min, not on dialysis), the FDA label recommends a reduced dose of 20 mg SC once daily.
  • Controlled trials have run up to 24 weeks (MMPOWER-3) and an open-label extension out to 168 weeks (TAZPOWER-OLE), and no mitochondria-specific safety signal has emerged across more than 2,000 patient-years of exposure. One earlier review stated that treatment beyond 4 weeks had not been studied; that no longer reflects the available data, though long-term safety in healthy individuals and for unapproved/compounded uses remains unestablished.
  • Rigorous human safety data for SS-31 as an unapproved/compounded product are scarce, with potential for serious harm; only the approved Forzinity product for Barth syndrome carries established regulatory safety data.

Reconstitution and handling

Formulation, Dosing & Storage

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

These details combine the approved product label with lower-tier vendor/community sources. Consumer dosing protocols are not validated by peer-reviewed trials and should be treated cautiously.

Approved product (Forzinity)

  • Supplied as a ready-to-use solution: 280 mg / 3.5 mL (80 mg/mL) — no reconstitution required.
  • Recommended dose: 40 mg subcutaneously once daily for patients ≥30 kg, taken at the same time each day regardless of food.
  • Severe renal impairment (eGFR <30 mL/min, not on dialysis): 20 mg SC once daily.

Doses used in research

  • The 40 mg SC once-daily arm was used in TAZPOWER (12 weeks) and MMPOWER-3 (24 weeks).
  • An escalated 60 mg/day SC dose is being evaluated in open-label mitochondrial-myopathy cohorts.
  • Acute IV studies use 0.05 mg/kg/h (~4 mg/hour) infusion over 1-3 hours (renal-stent/STEMI pilots); IV doses ranging 0.01-0.25 mg/kg/h over 4 hours have also been tested.

Non-clinical / community dosing (anecdotal, unverified)

  • Reported ranges of 5-40 mg once daily (5-10 mg/day for "general support," 20-40 mg/day for intensive models), over 4-6 or 4-12 week cycles.
  • Some sources suggest pairing with NAD+ precursors such as NMN — this is not an established recommendation.

Reconstitution & storage (for lyophilized research material)

  • Reconstituted SS-31 should be used within 28 days when stored at 36-46°F (2-8°C).
  • Lyophilized powder remains stable up to 2 years frozen at −20°C or below.
  • Avoid freeze-thaw cycles.

Pharmacokinetics relevant to dosing

  • Subcutaneous bioavailability ~92%; peak plasma at 15-30 min (IV) or 30-60 min (SC).
  • Plasma half-life ~3-4 hours (some sources 2.5-3 h IV), but mitochondrial tissue residence may extend ~8-12 hours due to cardiolipin binding (single-source claim citing Dai et al. 2015 rat study).
  • Reaches high intramitochondrial concentrations within minutes; concentrates in kidney, with additional uptake by heart, liver, skeletal muscle, and lungs; crosses the blood-brain barrier (low brain vs plasma levels). Cleared by renal filtration and peptidase degradation of the C-terminal dimethyltyrosine residue.

Sources

Ordered by evidence quality — the strongest first.

  1. Elamipretide: First Approval.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  2. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  3. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  4. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  5. Targeting mitochondrial dysfunction with elamipretide.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  6. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  7. SS-31 (Elamipretide): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 2Web · peptideinsight.com · 2026
  8. Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  9. Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  10. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  11. ALCAT1-mediated abnormal cardiolipin remodelling promotes mitochondrial injury in podocytes in diabetic kidney disease.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  12. A ROS-Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial Infarction.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  13. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  14. SS-31 (also known as Elamipretide®, Bendavia®, and ...(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  15. SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  16. SS-31 (Elamipretide) Dosing, Need to Know Information,… | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  17. SS-31 (Elamipretide) Protocol — Complete Dosing &… | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  18. SS-31 (Elamipretide): Mechanism, Half-life & Research Data | Subject 157(opens in a new tab)
    Tier 3Web · subject157.com
  19. SS-31 Half Life — What Researchers Must Know(opens in a new tab)
    Tier 3Web · realpeptides.co
  20. SS-31 Peptide (Elamipretide): The Ultimate Guide to Mitochondrial Health, Benefits, and Dosing — Peptide Resource(opens in a new tab)
    Tier 3Web · peptide-resource.com
  21. SS-31 Peptide: Uses, Dosage, Safety & Research(opens in a new tab)
    Tier 3Web · peptidedosages.com
  22. SS-31 Peptide Dosing Guide: Elamipretide Protocol & Safety (2026)(opens in a new tab)
    Tier 3Web · peptidedosingprotocols.com · 2026
  23. SS-31 (Elamipretide): Mechanism, Evidence, and Clinical Status | HealthRX.com(opens in a new tab)
    Tier 3Web · healthrx.com · 2026
  24. SS-31 Elamipretide: Phase 2/3 Clinical Trial Data & Mechanism(opens in a new tab)
    Tier 3Web · highpeptides.com · 2026
  25. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  26. SS-31 (Elamipretide) Peptide Therapy — Mechanism, Evidence & Clinical Pearls for Medical Professionals - Dr. Raj Singh(opens in a new tab)
    Tier 3Web · rsinghmd.com · 2025
  27. Beyond the injection: delivery systems reshaping retinal disease management.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  28. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD).(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  29. Elamipretide: A Review of Its Structure, Mechanism of Action ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov
  30. SS-31 Protocol - Dosing, Benefits & Warnings | Peptilogical(opens in a new tab)
    Tier 4Web · peptilogical.com